INIMMUNE CORP

Biotech · Private

Synthetic TLR4 agonist immunomodulators for broad-spectrum pathogen protection

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · inimmune.com

Sector: Biotech
Total capital: $14.2M

Federal grants: $1.4M; 4 awards · 2018–2020; Rank in peer group#376 of 392
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $12.8M; 5 awards · Health and Human S; Rank in Biotech#54 of 4373
Granted patents: 0; 6 pending

Capital timeline

Latest events

Sep 2023Federal contractHealth and Human S · Development Of Sas A Synthetic AS01-LIKE Adjuvant System For Influenza Vaccines$7.8M
Sep 2021Federal contractHealth and Human S · SBIR Topic 091 Phase II: Development Of A New TLR4 Agonist For The Treatment Of Allergic Rhinitis$1.8M
Sep 2021Federal contractHealth and Human S · Adjuvant Discovery For Vaccines And For Autoimmune And Allergic Diseases$599K
Aug 2020Federal grantHealth and Human S · Phase II · Novel synthetic TLR4 agonists$580K
Jun 2020Federal contractHealth and Human S · Production Of Synthetic Adjuvant System (sas): A Synergistic Combination Of Synthetic Adjuvant Components$2M
Aug 2019Federal grantHealth and Human S · Phase II · Novel synthetic TLR4 agonists$437K
Jul 2018Federal contractHealth and Human S · Igf::ot::igf "discovery Of New Small Molecule TLR4 Agonists For The Treatment Of Allergic Rhinitis"$631K

Show 2 earlier federal awards

Feb 2018Federal grantHealth and Human S · Phase I · Novel synthetic TLR4 agonists$177K
Feb 2018Federal grantHealth and Human S · Phase I · Novel synthetic TLR4 agonists$177K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 392 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 6

Jan 22, 2026PendingStimulator Of Interferon Genes AgonistsUSPTOApplication 18994389
PendingIntranasal Administration Of Toll-like Receptor 4 Agonists For Treating Allergic Rhinitis And Other Diseases And ConditionsUSPTOApplication PCTUS2025029048
PendingIntranasal Administration Of Toll-like Receptor 4 Agonists For Treating Allergic Rhinitis And Other Diseases And ConditionsUSPTOApplication 63647391

Show all 6 patent records

Stimulator Of Interferon Genes AgonistsJan 22, 2026 · Application 18994389Pending
Intranasal Administration Of Toll-like Receptor 4 Agonists For Treating Allergic Rhinitis And Other Diseases And ConditionsApplication PCTUS2025029048Pending
Intranasal Administration Of Toll-like Receptor 4 Agonists For Treating Allergic Rhinitis And Other Diseases And ConditionsApplication 63647391Pending
Functionalized Imidazopyrimidine Compounds And Uses ThereofApplication 63619707Pending
Stimulator Of Interferon Genes AgonistsApplication PCTUS2023028578Pending
Stimulator Of Interferon Genes AgonistsApplication 63391971Pending

VitriVaxSimilar federal contract value in Biotech · $14.5M in contracts
HDT BIO CORPSimilar federal contract value in Biotech · $14.5M in contracts
ENALARE THERAPEUTICS INCSimilar federal contract value in Biotech · $13M in contracts
ZATA PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $12.6M in contracts
INOVIO PHARMACEUTICALS, INC.Similar federal contract value in Biotech · $12M in contracts
Twist BioscienceSimilar federal contract value in Biotech · $12M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.